Stock ENTO ENTERO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Entero Therapeutics, Inc.

Equities

ENTO

US33749P4081

Market Closed - Nasdaq
Other stock markets
 15:59:50 2024-06-20 EDT 		5-day change 1st Jan Change
2.07 USD +6.70% Intraday chart for Entero Therapeutics, Inc. -5.91% -50.71%
05-20 Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index CI
05-17 First Wave BioPharma, Inc. will Change its Name to Entero Therapeutics, Inc CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Entero Therapeutics : Corporate Presentation (Entero Therapeutics June 2024 Corporate Presentation 2024.6.12 ADA Compliant)
PU
Entero Therapeutics : Corporate Fact Sheet (Entero Therapeutics Q224 Factsheet 2024.6.7 ADA Compliant 1)
PU
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
AQ
First Wave BioPharma Changes Name to Entero Therapeutics
AQ
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
AQ
First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month
AQ
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
AQ
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
AQ
First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
AQ
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
AQ
First Wave BioPharma Announces Completion of Business Combination with ImmunogenX, Adding Phase 3-Ready Latiglutenase to its Late-Stage GI-Focused Clinical Pipeline
AQ
First Wave BioPharma to Participate In ‘Fireside Chat’ at the 36th Annual Roth Conference
AQ
First Wave BioPharma, Inc. to Raise Approximately $4.0 Million of Gross Proceeds in Registered Direct Offering
AQ
First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024
AQ
First Wave BioPharma to Present at the DealFlow MicroCap Conference
AQ
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
AQ
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI
AQ
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
AQ
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
AQ
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ENTO Stock
  4. News Entero Therapeutics, Inc.
  5. Press Releases